Drug Development Quotes

The advent of AIDS circa 1980 has really forced medicine and biology to take enormous steps just for sheer survival. The same way war propels hard technology, AIDS has created wartime conditions in the field of biology that will have all sorts of spin-offs.

Engineers are behind the cars we drive, the pills we pop and the way we power our homes.

The problem of chemotherapy of bacterial infections could be solved neither by the experimental medical research worker nor by the chemist alone, but only by the two together working in very close cooperation over many years.

If you're trying to develop a new drug, that costs you a billion dollars to get through the FDA. If you want to start a software company, you can get started with maybe $100,000.

In most instances, biotechnology, though a radically different approach, is a sustaining technology: It's a dramatically improved way of targeting problems that we hadn't been able to solve with the conventional approach of mainstream pharmaceutical companies.

New drugs and surgical techniques offer promise in the fight against cancer, Alzheimer's, tuberculosis, AIDS, and a host of other life-threatening diseases. Animal research has been, and continues to be, fundamental to advancements in medicine.

There is no doubt that the Mindset failure is a major setback for Axovant, but it is not the end of the road.

Especially working in infectious disease, it's very interesting because these infectious diseases, these agents, they evolve over time. So it's very much an arms race and understanding how each changes to protect itself and to continue. And so it's very much this puzzle-solving but with this great urgency and importance in what you find.

When the price of a drug rises, it becomes profitable and the target of new competition.

NIH biodefense research is ultimately directed toward the development of new and effective medical countermeasures, including vaccines, therapeutics, and diagnostics against potential bioterror agents.

I want to make sure that our bio-similars capture a huge market share and help cancer patients around the world, which we are already doing in the developing world because we didn't have access to these drugs. Biocon enjoys a large reputation of giving them high-quality cancer drug.

Medicines are unusual commodities. Important drugs can save the lives and protect the health of millions. Their consumption can bring huge benefits, by helping patients to avoid infection and preventing serious damage to the economies of families, nations and even humanity at large.

The history of using mice to stand in for humans in medical experiments is replete with failures.

The discovery of artemisinin was an example of successful collective efforts.

Throughout my career, as both a physician and a scientist, I have drawn inspiration from Merck's unwavering commitment to scientific excellence. Over time, this commitment has brought forth an unparalleled number of breakthrough medicines and vaccines that improve the lives of patients around the world.

And there are lots of drug companies that are working on cure or medicine.

The Nobel Prize is fine, but the drugs I've developed are rewards in themselves.

In research, I wanted to establish the medicinal chemistry/bioassay conjugation as an academic pursuit, as exciting to the imagination as astrophysics or molecular biology.

Pharmaceutical companies have invested hundreds of millions of dollars in new HIV/AIDS treatments not out of altruism but because they can make up those research costs in sales.

I fell in love with the science at Merck.

Financial risk is always associated with drug discovery. But the benefit that a blockbuster drug can bring to the business can be phenomenal if you can take that risk.

We'll be investing in basic science research with the goal of curing disease.

If my drug Ragaglitazar had been successful, we would have been getting royalties of thousands of crore rupees every year.

It's easy to complain that pharmaceutical companies place profits over people and apparently care more about hair loss than TB. However, many in the pharmaceutical industry would be glad for the opportunity to reorient their research toward medicines that are truly needed, provided only that such research is financially sustainable.

Data-intensive graph problems abound in the Life Science drug discovery and development process.